Lasfar Ahmed, Zloza Andrew, de la Torre Andrew, Cohen-Solal Karine A
Department of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, USA; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA; Section of Surgical Oncology Research, Department of Surgery, Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.
Front Immunol. 2016 Dec 15;7:598. doi: 10.3389/fimmu.2016.00598. eCollection 2016.
IFN-λ is the newly established type III IFN with unique immunomodulatory functions. In contrast to the IFN-α/β family and to some extent IFN-γ, IFN-λ is apparently acting in specific areas of the body to activate resident immune cells and induces a local immunity, instrumental in preventing particular infections and also keeping transformed cells under control. Mucosal areas of lung and gastrointestinal tracts are now under scrutiny to elucidate the immune mechanisms triggered by IFN-λ and leading to viral protection. New evidence also indicates the crucial role of IFN-λ in promoting innate immunity in solid cancer models. Based on its unique biological activities among the IFN system, new immunotherapeutic approaches are now emerging for the treatment of cancer, infection, and autoimmune diseases. In the present review, we highlight the recent advances of IFN-λ immunomodulatory functions. We also discuss the perspectives of IFN-λ as a therapeutic agent.
IFN-λ是新确立的具有独特免疫调节功能的III型干扰素。与IFN-α/β家族以及在一定程度上与IFN-γ不同,IFN-λ显然在身体的特定区域发挥作用,激活驻留免疫细胞并诱导局部免疫,这有助于预防特定感染并控制转化细胞。目前,肺和胃肠道的黏膜区域正在接受研究,以阐明由IFN-λ触发并导致病毒防护的免疫机制。新证据还表明IFN-λ在实体癌模型中促进先天免疫方面的关键作用。基于其在干扰素系统中的独特生物学活性,目前正在出现用于治疗癌症、感染和自身免疫性疾病的新免疫治疗方法。在本综述中,我们重点介绍了IFN-λ免疫调节功能的最新进展。我们还讨论了IFN-λ作为治疗剂的前景。